PT-141 (Bremelanotide) vs Cerebrolysin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from purified pig brain proteins. It is approved in many countries for stroke, traumatic brain injury, and dementia.
Full details →Side-by-Side Comparison
| Aspect | PT-141 (Bremelanotide) | Cerebrolysin |
|---|---|---|
| Mechanism | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. | Contains multiple neurotrophic factors that promote neuroplasticity, reduce neuronal apoptosis, and support synaptic function. Has both neurotrophic and neuroprotective properties. |
| Typical Dosage | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. | Clinical dosing: 10-30ml IV daily for acute conditions. Research use: 5-10ml IM daily for cognitive enhancement. Treatment courses typically last 10-20 days. |
| Administration | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. | Administered via intramuscular or intravenous injection. IV administration is typically used in clinical settings. IM can be used for research purposes. |
| Side Effects | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. | Generally well-tolerated. May cause dizziness, headache, sweating, or injection site reactions. Rare cases of agitation or confusion. |
| Best For |
What They Have in Common
Both PT-141 (Bremelanotide) and Cerebrolysin are commonly used for: